Robert E. Landry - Dec 12, 2023 Form 4 Insider Report for REGENERON PHARMACEUTICALS, INC. (REGN)

Role
EVP Finance CFO
Signature
/s/**Robert E. Landry
Stock symbol
REGN
Transactions as of
Dec 12, 2023
Transactions value $
-$5,717,506
Form type
4
Date filed
12/14/2023, 04:08 PM
Previous filing
Dec 12, 2023
Next filing
Dec 29, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction REGN Common Stock Tax liability -$5.47M -6.38K -23.23% $856.71 21.1K Dec 12, 2023 Direct
transaction REGN Common Stock Options Exercise $379K +1K +4.74% $378.98 22.1K Dec 13, 2023 Direct
transaction REGN Common Stock Tax liability -$630K -723 -3.27% $871.12 21.4K Dec 13, 2023 Direct
holding REGN Common Stock 270 Dec 12, 2023 By 401(k) Plan

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction REGN Non-Qualified Stock Option (right to buy) Options Exercise $0 -1K -4.92% $0.00 19.3K Dec 13, 2023 Common Stock 1K $378.98 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The stock option award vests in four equal annual installments, commencing one year after the date of grant.